WE CLAIM:

1. A pharmaceutical composition comprising:

a) from about 0.1% to about 50 % by weight of lamotrigine or acid addition salt thereof;

b) from about 15.5% to about 70% by weight of microcrystalline cellulose;

from about 0.1% to about 14.5% by weight of sodium starch glycolate; and from about 0.1% to about 4.5% by weight of polyvinylpyrrolidone.

2. The pharmaceutical composition according to claim 1, further comprising from about 0.1% to about 14.5% by weight of lactose.

3. The pharmaceutical composition according to claim 1, wherein the composition comprises about 17% to about 70% by weight of microcrystalline cellulose, about 0.1% to about 13% by weight of sodium starch glycolate, and about 0.1% to about 4% by weight of polyvinylpyrrolidone.

4. The pharmaceutical composition according to claim 2, wherein the composition comprises about 17% to about 70% by weight of microcrystalline cellulose, about 0.1% to about 13% by weight of sodium starch glycolate, about 0.1% to about 4% by weight of polyvinylpyrrolidone, and about 0.1% to about 13% by weight of lactose.

5. The pharmaceutical composition according to claim 2, wherein the composition comprises about 20% to about 70% by weight of microcrystalline cellulose, about 0.1% to about 10% by weight of sodium starch glycolate, about 0.1% to about 3% by weight of polyvinylpyrrolidone, and about 0.1% to about 10% by weight of lactose.

6. The pharmaceutical composition according to claim 1, wherein the sodium starch glycolate is intragranular.

7. The pharmaceutical composition according to claim 1, wherein the sodium starch glycolate is extragranular.

8. The pharmaceutical composition according to claim 1, wherein the composition is a tablet.

9. The pharmaceutical composition according to claim 1, wherein at least 80% by weight of the lamotrigine or the acid addition salt thereof dissolves within 10 minutes.

10. The pharmaceutical composition according to claim 1, wherein at least 90% by weight of the lamotrigine or the acid addition salt thereof dissolves within 30 minutes.

11. The pharmaceutical composition according to claim 1, wherein the composition is stable after three months storage at 40°C and 75% RH with at least 98% of the lamotrigine or acid addition salt thereof remaining after three months.

12. A process for preparing a pharmaceutical composition, the process comprising wet granulating a composition that includes:

a) from about 0.1% to about 50 % by weight of lamotrigine or acid addition salt thereof;
b) from about 15.5% to about 70% by weight of microcrystalline cellulose;
c) from about 0.1% to about 14.5% by weight of sodium starch glycolate; and
d) from about 0.1% to about 4.5% by weight of polyvinylpyrrolidone.

13. The process according to claim 12, wherein the pharmaceutical composition further comprises from about 0.1% to about 14.5% by weight of lactose.

14. The process according to claim 12, wherein the composition comprises about 17% to about 70% by weight of microcrystalline cellulose, about 0.1% to about 13% by weight of sodium starch glycolate, and about 0.1% to about 4% by weight of polyvinylpyrrolidone.

15. The process according to claim 13, wherein the composition comprises about 17% to about 70% by weight of microcrystalline cellulose, about 0.1% to about 13% by weight of sodium starch glycolate, about 0.1% to about 4% by weight of polyvinylpyrrolidone, and about 0.1% to about 13% by weight of lactose.

16. The process according to claim 13, wherein the composition comprises about 20% to about 70% by weight of microcrystalline cellulose, about 0.1% to about 10% by weight of sodium starch glycolate, about 0.1% to about 3% by weight of polyvinylpyrrolidone, and about 0.1% to about 10% by weight of lactose.

17. The process according to claim 11, wherein the pharmaceutical composition comprises about 50% by weight of lamotrigine, about 20% to about 30% by weight of microcrystalline cellulose, about 10% to about 14.5% by weight of lactose, about 4% to about 10% by weight of sodium starch glycolate and about 0.1% to about 4.5% by weight of polyvinylpyrrolidone.

18. The process according to claim 12 or 13, wherein the lamotrigine or its acid addition salt, microcrystalline cellulose, sodium starch glycolate, polyvinylpyrrolidone and/or lactose are blended and then granulated with water.

19. The process according to claim 12 or 13, wherein the lamotrigine or its acid addition salt, microcrystalline cellulose, sodium starch glycolate and/or lactose are blended and then granulated with an aqueous solution of polyvinylpyrrolidone.

20. The process according to claim 18, further comprising screening the wet mass to obtain granules.

21. The process according to claim 19, further comprising screening the wet mass to obtain granules.

22. The process according to claim 20, further comprising drying and sieving the granules.

23. The process according to claim 21, further comprising drying and sieving the granules.

24. The process according to claim 22, further comprising compressing the granules to form tablets.

25. The process according to claim 23, further comprising compressing the granules to form tablets.

26. The process according to claim 12, wherein the sodium starch glycolate is intragranular.

27. The process according to claim 12, wherein the sodium starch glycolate is extragranular.

28. A method of treating a medical condition responsive to lamotrigine, the method comprises administering a pharmaceutical composition of lamotrigine, the composition comprising:

(a) from about 0.1% to about 50% by weight of lamotrigine or acid addition salt thereof;

(b) from about 15.5% to about 70% by weight of microcrystalline cellulose;

(c) from about 0.1% to about 14.5% by weight of sodium starch glycolate; and

(d) from about 0.1% to about 4.5% by weight of polyvinylpyrrolidone.

29. The method according to claim 28, wherein the pharmaceutical composition further comprises from about 0.1% to about 14.5% by weight of lactose.